


Appendix 4 (as supplied by the authors)

Exposure risk windows used in other observational studies¹⁻²¹ employing a risk interval design for assessing vaccine-induced autoimmunity



* ITP = Immune thrombocytopenia purpura; ADEM = Acute disseminated encephalomyelitis; MS = Multiple Sclerosis; GBS = Guillain-Barré syndrome; AIHA = Autoimmune haemolytic anemia; ON = Optic neuritis

References

1. Chao C, Klein N, Velicer C, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. *J Intern Med.* 2012;271(2):193-203. doi:10.1111/j.1365-2796.2011.02467.x.
2. Klein N, Hansen J, Chao C, et al. Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. *Arch Pediatr Adolesc Med.* 2012:1-9. doi:10.1001/archpediatrics.2012.1451.
3. Rowhani-Rahbar A, Klein N, Dekker C, et al. Biologically plausible and evidence-based risk intervals in immunization safety research. *Vaccine.* 2012. doi:10.1016/j.vaccine.2012.07.024.
4. France E, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. *Pediatrics.* 2008;121(3):92. doi:10.1542/peds.2007-1578.
5. Miller E, Waight P, Farrington C, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. *Arch Dis Child.* 2001;84(3):227-229. doi:10.1136/adc.84.3.227.
6. Stowe J, Kafatos G, Andrews N, Miller E. Idiopathic thrombocytopenic purpura and the second dose of MMR. *Arch Dis Child.* 2008;93(2):182-183. doi:10.1136/adc.2007.126003.
7. Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. *Hum Vaccin.* 2007;3(2):59-63. <http://www.ncbi.nlm.nih.gov/pubmed/17312400>.
8. Gold M, Dugdale S, Woodman R, McCaul K. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. *Vaccine.* 2010;28(26):4308-4311. doi:10.1016/j.vaccine.2010.04.021.
9. Confavreux C, Suissa S, Saddinger P, Bourdès V, Vukusic S, Group V in MSS. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. *N Engl J Med.* 2001;344(5):319-326. doi:10.1056/NEJM200102013440501.
10. Hocine M, Farrington C, Touzé E, et al. Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. *Vaccine.* 2007;25(31):5938-5943. doi:10.1016/j.vaccine.2007.05.032.
11. Hughes R, Charlton J, Latinovic R, Gulliford M. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. *Arch Intern Med.* 2006;166(12):1301-1304. doi:10.1001/archinte.166.12.1301.
12. Juurlink D, Stukel T, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. *Arch Intern Med.* 2006;166(20):2217-2221. doi:10.1001/archinte.166.20.2217.
13. Lasky T, Terracciano G, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and

- 1993-1994 influenza vaccines. *N Engl J Med.* 1998;339(25):1797-1802.
doi:10.1056/NEJM199812173392501.
14. Geier M, Geier D, Zahalsky A. Influenza vaccination and Guillain Barre syndrome small star, filled. *Clin Immunol.* 2003;107(2):116-121. doi:10.1016/S1521-6616(03)00046-9.
 15. Yih W, Lee G, Lieu T, et al. Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. *Am J Epidemiol.* 2012;175(11):1120-1128. doi:10.1093/aje/kws197.
 16. Wise M, Viray M, Sejvar J, et al. Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-based Surveillance Among 45 Million Americans. *Am J Epidemiol.* 2012;175(11):1110-1119. doi:10.1093/aje/kws196.
 17. De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. *JAMA.* 2012;308(2):175-181. doi:10.1001/jama.2012.7342.
 18. Naleway A, Belongia E, Donahue J, Kieke B, Glanz J, Datalink VS. Risk of immune hemolytic anemia in children following immunization. *Vaccine.* 2009;27(52):7394-7397.
doi:10.1016/j.vaccine.2009.09.023.
 19. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. *N Engl J Med.* 2004;350(9):896-903.
doi:10.1056/NEJMoa030595.
 20. Stowe J, Andrews N, Wise L, Miller E. Bell's palsy and parenteral inactivated influenza vaccine. *Hum Vaccin.* 2006;2(3):110-112. <http://www.ncbi.nlm.nih.gov/pubmed/17012908>.
 21. Payne D, Rose C, Kerrison J, Aranas A, Duderstadt S, McNeil M. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. *Arch Neurol.* 2006;63(6):871-875.
doi:10.1001/archneur.63.6.871.